selectivity Cancer Research Results

selectivity, selectivity: Click to Expand ⟱
Source:
Type:
The selectivity of cancer products (such as chemotherapeutic agents, targeted therapies, immunotherapies, and novel cancer drugs) refers to their ability to affect cancer cells preferentially over normal, healthy cells. High selectivity is important because it can lead to better patient outcomes by reducing side effects and minimizing damage to normal tissues.

Achieving high selectivity in cancer treatment is crucial for improving patient outcomes. It relies on pinpointing molecular differences between cancerous and normal cells, designing drugs or delivery systems that exploit these differences, and overcoming intrinsic challenges like tumor heterogeneity and resistance

Factors that affect selectivity:
1. Ability of Cancer cells to preferentially absorb a product/drug
-EPR-enhanced permeability and retention of cancer cells
-nanoparticle formations/carriers may target cancer cells over normal cells
-Liposomal formations. Also negatively/positively charged affects absorbtion

2. Product/drug effect may be different for normal vs cancer cells
- hypoxia
- transition metal content levels (iron/copper) change probability of fenton reaction.
- pH levels
- antiOxidant levels and defense levels

3. Bio-availability
Ovarian, Ovarian Cancer: Click to Expand ⟱
Ovarian Cancer
Scientific Papers found: Click to Expand⟱
5977- AgNPs,  CDT,    Silver Nitroprusside as an Efficient Chemodynamic Therapeutic Agent and a Peroxynitrite nanogenerator for Targeted Cancer Therapy
- in-vivo, Ovarian, A2780S - NA, Ovarian, SKOV3
Fenton↑, ROS↑, eff↑, angioG↓, p‑Akt↓, EPR↑, selectivity↑, selectivity↑, eff↑, Cyt‑c↑, HO-1↑,
4951- PEITC,    ROS accumulation by PEITC selectively kills ovarian cancer cells via UPR-mediated apoptosis
- in-vitro, Ovarian, PA1 - in-vitro, Ovarian, SKOV3
ROS↑, TumCP↓, GSH↓, selectivity↑, UPR↑, CHOP↑, ER Stress↑, GRP78/BiP↑, PERK↑, ATF6↑, eff↓, TumCG↓, Apoptosis↑, toxicity↓,
4954- PEITC,    Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by β-phenylethyl isothiocyanate
- vitro+vivo, Ovarian, SKOV3
ROS↑, GSH↓, selectivity↑, mtDam↑, TumCD↑, OS↑, eff↑, *toxicity↓, H2O2↑, NO↑, eff↓, GPx↓, Dose↝, eff↑,
5327- TFdiG,    Theaflavin-3, 3'-digallate induces apoptosis and G2 cell cycle arrest through the Akt/MDM2/p53 pathway in cisplatin-resistant ovarian cancer A2780/CP70 cells
- in-vitro, Ovarian, A2780S
TumCG↓, selectivity↑, TumCCA↑, Apoptosis↑, P53↑, BAX↑, BAD↑, cl‑Casp3↑, p‑Akt↓, MDM2↓, MMP↓, Cyt‑c↑,
5330- TFdiG,  Cisplatin,    Theaflavin-3,3′-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, OVCAR-3
selectivity↑, ChemoSen↑, DNAdam↑, GSH↓, CTR1↑,
1936- TQ,    Thymoquinone induces apoptosis and increase ROS in ovarian cancer cell line
- in-vitro, Ovarian, CaOV3 - in-vitro, Nor, WRL68
selectivity↑, TumCP↓, MMP↓, Bcl-2↓, BAX↑, ROS↑,
5020- UA,    Anticancer activity of ursolic acid on human ovarian cancer cells via ROS and MMP mediated apoptosis, cell cycle arrest and downregulation of PI3K/AKT pathway
- in-vitro, Ovarian, NA
tumCV↓, selectivity↑, BAX↑, Bcl-2↓, Apoptosis↑, ROS↑, TumCCA↑, Akt↓, PI3K↓,
3133- VitC,    Vitamin C supplementation had no side effect in non-cancer, but had anticancer properties in ovarian cancer cells
- in-vitro, Ovarian, NA
*SVCT-2↑, *GLUT1↓, SVCT-2↓, GLUT1↑, TumCP↓, CDK2↓, PARP↓, selectivity↑,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Fenton↑, 1,   GPx↓, 1,   GSH↓, 3,   H2O2↑, 1,   HO-1↑, 1,   ROS↑, 5,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,   mtDam↑, 1,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 2,   Apoptosis↑, 3,   BAD↑, 1,   BAX↑, 3,   Bcl-2↓, 2,   cl‑Casp3↑, 1,   Cyt‑c↑, 2,   MDM2↓, 1,   TumCD↑, 1,  

Transcription & Epigenetics ⓘ

tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ATF6↑, 1,   CHOP↑, 1,   ER Stress↑, 1,   GRP78/BiP↑, 1,   PERK↑, 1,   UPR↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 1,   PARP↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,   TumCG↓, 2,  

Migration ⓘ

TumCP↓, 3,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   EPR↑, 1,   NO↑, 1,  

Barriers & Transport ⓘ

CTR1↑, 1,   GLUT1↑, 1,   SVCT-2↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   Dose↝, 1,   eff↓, 2,   eff↑, 4,   selectivity↑, 9,  

Functional Outcomes ⓘ

OS↑, 1,   toxicity↓, 1,  
Total Targets: 46

Pathway results for Effect on Normal Cells:


Barriers & Transport ⓘ

GLUT1↓, 1,   SVCT-2↑, 1,  

Functional Outcomes ⓘ

toxicity↓, 1,  
Total Targets: 3

Scientific Paper Hit Count for: selectivity, selectivity
2 Phenethyl isothiocyanate
2 Aflavin-3,3′-digallate
1 Silver-NanoParticles
1 chemodynamic therapy
1 Cisplatin
1 Thymoquinone
1 Ursolic acid
1 Vitamin C (Ascorbic Acid)
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:20  Cells:%  prod#:%  Target#:1110  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page